Physiology of Incretins in Health and Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are gut peptides which are secreted by endocrine cells in the intestinal mucosa. Their plasma concentrations increase quickly following food ingestion, and carbohydrate, fat, and protein have all been shown to stimulate GLP-1 and GIP secretion. Although neural and hormonal mechanisms have also been proposed to regulate incretin hormone secretion, direct stimulation of the enteroendocrine cells by the presence of nutrients in the intestinal lumen is probably the most important factor in humans. The actions of the incretin hormones are crucial for maintaining normal islet function and glucose homeostasis. Furthermore, it is also now being recognized that incretin hormones may have other actions in addition to their glucoregulatory effects. Studies have shown that GLP-1 and GIP levels and actions may be perturbed in disease states, but interpretation of the precise relationship between disease and incretins is difficult. The balance of evidence seems to suggest that alterations in secretion and/or action of incretin hormones arise secondarily to the development of insulin resistance, glucose intolerance, and/or increases in body weight rather than being causative factors. However, these impairments may contribute to the deterioration of glycemic control in diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 7×
“GLP-1 has potent effects on pancreatic βcells; it enhances the meal-stimulated release of insulin (the “incretin effect”) in a glucosedependent manner, stimulates all stages of insulin biosynthesis, and improves overall β-cell function [62].”
BackgroundInfluentialNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“In patients with type 2 diabetes, the incretin effect is clearly reduced [109, 110], which results in an inappropriately low insulin response to the 25-g-OGTT”
BackgroundGut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 1×
“More recently, a mechanism involving activation of the sweet taste-receptor, gustducin, has also been proposed [33].”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Knock-out of the GIP receptor confers resistance to diet-induced obesity in mice [88], although there is no clear evidence at present to suggest an association between GIP and obesity in humans.”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 11×
“Furthermore, DPP-4 inhibition, which leads to increased levels of endogenous intact (active) GLP-1 and GIP, is associated with lower total incretin levels, in both animals [57] and humans [34], suggesting that their secretion has been suppressed.”
BackgroundInfluentialSelf-citationKatsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789 · cited 1×
“Rev Diabet Stud (2011) 8:293-306 Copyright © by Lab & Life Press/SBDR from an enteroendocrine cell line in vitro [48], and GLP-1 release from the perfused rat colon increases following perfusion with bile acids [49].”
BackgroundGlucose Sensing in L Cells: A Primary Cell Study
Reimann, F., Habib, A. M., Tolhurst, G., Parker, H. E., Rogers, G. J., & Gribble, F. M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.002 · Cited by 733 · cited 9×
“Enteroendocrine cells express a number of different G-protein-coupled receptors (GPR) [31, 42], some of which have been proposed to mediate the stimulatory effects of dietary fats on incretin hormones.”
BackgroundInfluentialCreutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587 · cited 1×
“GPR40, GPR120) and which have been suggested to mediate free fatty acid stimulation of GLP-1 [46, 47].”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · cited 1×
“The extent of the GLP-1 response is related to both meal composition and meal size [60].”
BackgroundT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · cited 3×
“fied and reproduced with kind permission from [122] (Springer Science+Business Me-”
BackgroundMethodInfluentialSelf-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 4×
“GLP1 also potently suppresses α-cell secretion of glucagon, again in a glucose-dependent manner.”
BackgroundInfluentialVerdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 4×
“Most studies have found no impact of changes in body weight on GIP levels [27, 94, 97], although in other studies, both modestly reduced [93] and increased [98] GIP levels have been reported in obese subjects.”
BackgroundResultInfluentialEdwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“Thus, when infused into healthy humans, exendin 9-39 was associated with increased postprandial glucose excursions [68].”
BackgroundParker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324 · cited 11×
“Enteroendocrine cells express a number of different G-protein-coupled receptors (GPR) [31, 42], some of which have been proposed to mediate the stimulatory effects of dietary fats on incretin hormones.”
BackgroundInfluentialMeier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationEvidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · cited 1×
“In rodent studies, investigating the role of GLP-1 on food intake, GLP-1 receptor antagonism using exendin 9-39 has given conflicting results [77-79].”
ResultAhrén, B., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1030 · Cited by 292 · cited 1×
“Sham-feeding does not alter GLP-1 concentrations [53], while basal GLP-1 and GIP concentrations remain unchanged in the preabsorptive (cephalic) period [54], and are unaffected by the non-specific muscarinic blocker atropine.”
BackgroundHare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Self-citationMoens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Impaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
Heller, R. S., Kieffer, T. J., & Habener, J. F. (1997) · Diabetes · doi:10.2337/diab.46.5.785 · Cited by 179
Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137 · cited 1×
“Incretin hormone concentrations appear normal in non-diabetic offspring of type 2 diabetes patients [101] and in first-degree relatives of diabetic subjects [102], whereas, in identical twins discordant for diabetes, reduced GLP-1 levels were observed in the affected twin only [103].”
BackgroundSelf-citationWettergren, A., Petersen, H., ørskov, C., Christiansen, J., Sheikh, S. P., & Holst, J. J. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409092462 · Cited by 133 · cited 1×
“Sham-feeding does not alter GLP-1 concentrations [53], while basal GLP-1 and GIP concentrations remain unchanged in the preabsorptive (cephalic) period [54], and are unaffected by the non-specific muscarinic blocker atropine.”
BackgroundLindgren, O., Mari, A., Deacon, C. F., Carr, R. D., Winzell, M. S., Vikman, J., & Ahrén, B. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0366 · Cited by 111
Self-citationSalehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108 · cited 2×
“Since this finding, several clinical studies have demonstrated that endogenous GLP-1 plays a major role in regulating pancreatic islet responses to glucose [69, 70].”
BackgroundResultGlucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94 · cited 1×
“Calculation of the amount of GLP-1 present in the upper intestine indicates that this is more than sufficient to account for the GLP-1 response to oral glucose [59].”
BackgroundGLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87 · cited 1×
“Diabetesinduced peripheral nerve degeneration was reduced in studies using a GLP-1 receptor agonist or a DPP-4 inhibitor to enhance endogenous GLP-1 levels [84, 85], while hyperglycemia-induced reductions of motor nerve conduction velocity were attenuated by GLP-1 receptor agonism in diabetic mice [86].”
BackgroundSelf-citation
Cited by
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
“Oral protein and lipid typically produce slower-onset, more sustained increases than does glucose (95, 122, 128, 131, 195, 235, 336, 442, 600, 762).”
BackgroundAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
Li, X., Leng, S., & Song, D. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s74042 · Cited by 292
Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158
Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
Ahrén, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64
Metadata
- Authors
- Deacon, C. F., & Ahrén, B.
- Venue
- The Review of Diabetic Studies
- Publisher
- Raiya Academic International LLC
- Published
- 2011
- Volume
- 8
- Issue
- 3
- Pages
- 293-306
- ISSN
- 1613-6071 (ISSN-L)
- 1614-0575
- OpenAlex
- W1583362713
- Cited by
- 126
- References
- 37
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.